Simulations Plus, Inc. (SLP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Simulations Plus, Inc. (SLP) Healthcare & Pipeline Overview

Simulations Plus, Inc. provides modeling and simulation software for drug development, utilizing AI to predict molecular properties and drug interactions. Serving pharmaceutical, biotech, and agrochemical sectors, SLP's solutions streamline R&D processes, offering a competitive edge in the healthcare information services industry with a $373M market cap.

What Is the Investment Thesis for SLP?

The company's GastroPlus software and related simulation tools are essential for predicting drug interactions and optimizing formulations, addressing a critical need in the pharmaceutical and biotech industries. With a gross margin of 62.0%, SLP demonstrates strong profitability in its core operations. Growth catalysts include the increasing adoption of AI-driven drug discovery tools and the expansion of its software into new therapeutic areas. The increasing regulatory requirements for drug safety and efficacy also drive demand for SLP's simulation and modeling solutions. However, investors should be aware of the company's negative profit margin of -78.0% and beta of 1.28, indicating higher volatility compared to the market. The absence of a dividend may also deter some investors. The company's future success depends on its ability to maintain its technological edge and expand its market share in a competitive landscape.

Based on FMP financials and quantitative analysis

SLP Key Highlights

Market Cap of $373M reflects Simulations Plus, Inc.'s position as a key player in the healthcare information services industry.

• Gross Margin of 62.0% indicates strong profitability in its core software and services offerings.
• Profit Margin of -78.0% highlights potential concerns regarding overall financial performance and cost management.
• Beta of 1.28 suggests higher volatility compared to the broader market, potentially due to its growth-oriented business model.
• No Dividend Yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.

Who Are SLP's Competitors?

SLP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SLP's Key Strengths?

Specialized AI-driven simulation software for drug development.

• Strong gross margin of 62.0%.
• Established customer base in pharmaceutical and biotechnology industries.
• Comprehensive product suite covering various aspects of drug development.

What Are SLP's Weaknesses?

Negative profit margin of -78.0%.

• High beta of 1.28 indicating higher volatility.
• Reliance on specific software products and markets.
• Limited geographic diversification.

What Could Drive SLP Stock Higher?

Launch of new AI-driven software products for specific therapeutic areas by Q4 2026.

• Increasing adoption of AI and machine learning in drug discovery and development.
• Expansion of consulting and training services to enhance customer support.
• Strategic partnerships and acquisitions to expand product portfolio and market reach.

What Are the Key Risks for SLP?

Rich valuation — a P/E of 44.95 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Intense competition from other healthcare IT companies.
• Rapid technological changes in AI and machine learning.
• Regulatory changes affecting drug development processes.
• Negative profit margin impacting financial stability.
• High beta indicating higher volatility compared to the market.

What Are the Growth Opportunities for SLP?

• Expansion into New Therapeutic Areas: Simulations Plus can expand its software solutions into new therapeutic areas such as oncology, immunology, and personalized medicine. The market for AI-driven drug discovery in oncology alone is projected to reach $1 billion by 2030, offering a significant growth opportunity. By tailoring its GastroPlus and other simulation tools to these specific areas, SLP can attract new customers and increase its revenue streams. This expansion requires investment in R&D and strategic partnerships with research institutions and pharmaceutical companies.
• Geographic Expansion into Emerging Markets: Simulations Plus can target emerging markets such as China, India, and Brazil, where the pharmaceutical and biotechnology industries are rapidly growing. These markets offer a large untapped customer base for SLP's software solutions. The pharmaceutical market in China, for example, is expected to reach $200 billion by 2028. To succeed in these markets, SLP needs to establish local partnerships, adapt its software to local regulatory requirements, and invest in sales and marketing efforts.
• Strategic Partnerships and Acquisitions: Simulations Plus can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with complementary technology providers or acquiring companies with innovative solutions can enhance SLP's competitive position. For example, acquiring a company specializing in AI-driven clinical trial design could significantly strengthen SLP's offerings. These partnerships and acquisitions require careful due diligence and integration to ensure long-term value creation.
• Increased Adoption of AI and Machine Learning: The increasing adoption of AI and machine learning in drug discovery and development presents a significant growth opportunity for Simulations Plus. As pharmaceutical companies seek to leverage AI to accelerate their R&D processes, the demand for SLP's AI-driven simulation tools is expected to increase. The global AI in drug discovery market is projected to reach $4 billion by 2027. SLP needs to continue investing in AI research and development to maintain its technological edge and capitalize on this growing trend.
• Enhanced Consulting and Training Services: Simulations Plus can expand its consulting and training services to provide more comprehensive support to its customers. By offering customized training programs and expert consulting services, SLP can help its customers maximize the value of its software solutions. This can lead to increased customer satisfaction and retention, as well as new revenue opportunities. The market for pharmaceutical consulting services is estimated at $50 billion annually, providing a substantial opportunity for SLP to grow its services business.

What Are SLP's Competitive Advantages?

• Proprietary Technology: SLP's AI-driven simulation and modeling software is based on proprietary algorithms and models.
• Industry Expertise: The company has deep expertise in drug discovery and development, providing a competitive advantage.
• Established Customer Base: SLP has a long-standing customer base in the pharmaceutical and biotechnology industries.
• Regulatory Compliance: SLP's software helps customers comply with regulatory requirements, creating a barrier to entry for new competitors.

What Does SLP Do?

Simulations Plus, Inc., founded in 1996 and headquartered in Lancaster, California, is a leading provider of simulation and modeling software for drug discovery and development. The company's core business revolves around creating sophisticated software tools that predict molecular properties and simulate drug interactions, leveraging artificial intelligence and machine learning technologies. These tools are designed to accelerate research and development processes, reduce costs, and improve the efficiency of drug development for pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus operates through four key segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. Its flagship product, GastroPlus, simulates the absorption and drug interaction of compounds in humans and animals. Other products include DDDPlus and MembranePlus, which offer specialized simulation capabilities. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym, which focus on specific disease areas. In addition to its core software offerings, Simulations Plus provides the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Predictor, a chemistry-based program that predicts molecular properties. MedChem Designer, MonolixSuite, and PKPlus are also part of their product suite. The company further offers population modeling and simulation contract research services, training, and clinical-pharmacology-based consulting services to support regulatory submissions. Simulations Plus has established a strong presence in the pharmaceutical and biotechnology industries, serving a diverse clientele ranging from large pharmaceutical corporations to smaller biotech startups. Its software solutions are used to optimize drug formulations, predict clinical outcomes, and support regulatory filings, making it a critical partner in the drug development lifecycle.

What Products and Services Does SLP Offer?

• Develops software for drug discovery and development.
• Offers AI and machine learning-based technology for predicting molecular properties.
• Provides GastroPlus for simulating drug absorption and interaction.
• Offers DDDPlus and MembranePlus simulation products.
• Provides DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym based on mechanistic models.
• Offers ADMET Predictor for predicting molecular properties.
• Provides MedChem Designer, MonolixSuite, and PKPlus.
• Offers population modeling and simulation contract research services.

How Does SLP Make Money?

• Software Licensing: Generates revenue through licensing its software products to pharmaceutical, biotechnology, and related companies.
• Consulting Services: Provides consulting services related to pharmacometrics and clinical pharmacology.
• Training Programs: Offers training programs to help customers effectively use its software.
• Contract Research: Conducts contract research for population modeling and simulation.

What Industry Does SLP Operate In?

Simulations Plus, Inc. operates within the healthcare information services industry, which is experiencing significant growth due to the increasing demand for advanced drug discovery and development tools. The market is driven by the need for faster, more efficient, and cost-effective drug development processes. The competitive landscape includes companies like Kindly MD, Inc. (NAKA), which also offer solutions in the healthcare sector. Simulations Plus differentiates itself through its specialized focus on AI-driven simulation and modeling, catering to a niche market within the broader healthcare IT space. The industry is characterized by continuous innovation and regulatory changes, requiring companies to adapt and evolve to maintain a competitive edge.

Who Are SLP's Key Customers?

• Pharmaceutical Companies: Large and small pharmaceutical companies use SLP's software for drug development.
• Biotechnology Companies: Biotech companies utilize SLP's solutions to accelerate their research and development processes.
• Agrochemical Companies: Agrochemical companies use SLP's software for developing new agricultural products.
• Academic and Regulatory Agencies: Academic institutions and regulatory agencies use SLP's tools for research and regulatory purposes.

Over the past six months, Simulations Plus, Inc. insiders filed 21 SEC Form 4 transactions — 14 sales and 7 purchases. On net that is roughly 40K shares disposed (about $815K), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Simulations Plus, Inc.

Revenue for Simulations Plus, Inc. came in at $21.9M during Q3 FY2026, a 9.9% contraction versus the preceding quarter. The company recorded net income of $3.6M, with diluted EPS of $0.18. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, SLP averaged $0.10 in diluted EPS.

SLP Valuation & Market Position

With a $373M market cap, Simulations Plus, Inc. sits in the small-cap segment of the market. Analyst price targets span from $18.50 to $18.50, with a consensus of $18.50. At the current price of $18.42, that implies approximately 0% upside potential. Relative to its peer group, SLP's quantitative score of 80/100 is above the peer average of 55/100.

Return on equity for Simulations Plus, Inc. stands at 6.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.3%, showing how much profit it generates from its asset base. SLP trades at a trailing price-to-earnings ratio of 44.95, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

Simulations Plus, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 17.07 places it in the safe zone, indicating low near-term bankruptcy risk.

Simulations Plus, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 14.2% above estimates on average.

Company Profile

Simulations Plus, Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Research Triangle Park, US. The company is led by CEO Shawn O'Connor. SLP has traded publicly since 1997.

SLP Financials

SLP Latest News

SLP Analyst Consensus

SLP MoonshotScore

What Investors Ask About Simulations Plus, Inc. (SLP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources